Lyra Therapeutics

LYRA · NASDAQ

$0.19−$0.16 (−45.71%)TodayMarket closed · Oct 20, 3:54 PM ET

Prev close $0.35

LYRA analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 28, 2025

Bull case

Lyra Therapeutics is a clinical-stage company focused on developing innovative therapeutic solutions for ENT diseases, with LYR-210 and LYR-220 as its flagship product candidates. The ENLIGHTEN-2 trial for LYR-210 demonstrated statistically significant improvements in both primary and secondary endpoints for chronic rhinosinusitis symptoms, including a p-value of 0.0078 for the primary endpoint and additional positive metrics for the broader patient population. These compelling trial results underline the potential for successful commercialization, providing a strong foundation for a favorable outlook on the stock's performance.

Bear case

The fundamental outlook for Lyra Therapeutics's stock is adversely impacted by significant risks associated with its developmental candidates, which may not meet peak commercial revenue estimates due to factors such as market size and penetration rates. Additionally, the company's ability to secure necessary capital resources to fund ongoing operations poses a substantial financial risk. Continued challenges in program development and commercialization further exacerbate the uncertainty surrounding the company's future profitability and operational viability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.